In this episode of OnAir, host Daniela Gautschi is joined by two experts in ASV therapy* and real-world evidence: Prof. Michael Arzt (READ-ASV registry1, 2) and Prof. Renaud Tamisier (FACE-cohort3, 4 and FACIL-VAA5 registries).

Experience shows that ASV can improve symptoms and quality of life for some patients with central sleep apnoea. But which patients are most likely to benefit and why? By performing large-scale database analyses, Prof. Arzt and Prof. Tamisier have been able to identify clinically meaningful clusters of CSA patients, explore phenotypes that have yet to be studied by RCTs, and shed light on the critical role played by sleep, respiratory and cardiovascular comorbidities.

Listen now to understand how this research could transform the diagnosis, treatment and prognosis of patients with persistent CSA and Treatment-Emergent CSA.

Guests:

Prof. Michael Arzt - Professor of Internal Medicine, University Hospital Regensburg, Germany

Prof. Renaud Tamisier - Professor of Clinical Physiology, Grenoble Alpes University and Director of the Sleep Exploration Centre, Grenoble Alpes University Hospital, France

Host:

Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.

References and useful links:

1. Arzt M, Munt O, Pépin J-L, et al. Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV): protocol and cohort profile. ERJ Open Res 2023; 9: 00618-2022 [DOI: https://doi.org/10.1183/23120541.00618-2022]
2. Arzt M, Munt O, Pépin JL, Heinzer R, Kübeck R, von Hehn U, Ehrsam-Tosi D, Benjafield AV, Woehrle H. Effects of Adaptive Servo-Ventilation on Quality of Life: The READ-ASV Registry. Ann Am Thorac Soc. 2024 Jan 19. doi: https://doi.org/10.1513/AnnalsATS.202310-908OC
3. Tamisier R, Damy T, Bailly S FACE study investigators, et al; Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data. Thorax 2022;77:178-185. https://thorax.bmj.com/content/77/2/178
4. Tamisier R, Damy T, Bailly S, Goutorbe F, Davy JM, Lavergne F, Palot A, Verbraecken JA, d'Ortho MP, Pépin JL; FACE investigators; Steering committee members; d'Ortho MP, Pépin JL, Davy JM, Damy T, Tamisier R; FACE study investigators. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med. 2024 Jan;113:412-421. doi: https://doi.org/10.1016/j.sleep.2023.07.014
5. Observational Multicenter Cohort Study of French Patients With a Central or Combined Syndrome of Sleep Apnea With a Predominant Central SAS Treated by Adaptive Servo-Ventilation (FACIL-VAA) https://clinicaltrials.gov/study/NCT02835638

• ERS workshop replay: The indication of use of ASV therapy, from evidence to clinical practice

*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.

The podcast OnAir, with Clinical Respiratory News (CRN) is a medical education non-promotional for healthcare professionals organised by ResMed. Learn more at https://webinars.resmed.eu/podcasts-list/.

This podcast is intended for healthcare professionals only.

Disclaimer:

• This programme is non promotional and is sponsored by ResMed.
• The speakers are being compensated and/or receiving an honorarium from ResMed in connection with this programme.
• The content contained in this programme was jointly developed by the speakers and ResMed, and is not eligible for continuing medical education (CME) credits.

Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health.

© ResMed